Trial · NCT01391611
Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
NCT01391611, Phase 2, Terminated, Kristen Ganjoo; results first posted 2017-04-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST). Trials, record NCT01391611. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01391611
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)
- NCT number
- NCT01391611
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 25 participants, actual
- Lead sponsor
- Kristen Ganjoo
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- Pazopanib
- First posted
- 2011-07-12
- Last updated
- 2017-04-07
- Results first posted
- 2017-04-07
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD) | 24 weeks | 4-mo non-progression rate "Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progression, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression |
| Secondary | Response Per Choi Criteria | 6 months | Response per Choi criteria * Complete response - Disappearance of all lesions; no new lesion * Partial response - A decrease in size of \> or = 10% or a decrease in tumor density (HU) \> or = 15% on CT. No new lesions. No obvious progression of nonmeasurable disease. * Stable disease - Does not meet the criteria for CR, PR, or PD. No symptomatic deterioration attributed to tumor progression. * Progressive disease - An increase in tumor size of \> or = 10% and does not meet criteria of PR by tumor density (HU) on CT. New lesions. New intratumoral nodules or increase in the size of the existing intratumoral nodules. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD) | 24 weeks | months | MEDIAN | |
| SECONDARY | Response Per Choi Criteria | 6 months | Choi criteria measurements were not done due to technical difficulties. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Non-progression Rate Based on RECIST 1.0 Criteria (CR+PR+SD) | Pazopanib Arm | 1.9 | 95% Confidence Interval 1.6 to 5.2 | months | |
| Response Per Choi Criteria | Pazopanib Arm | 0 |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib Arm | 25 | |
| Overall Study | COMPLETED | Pazopanib Arm | 3 | |
| Overall Study | NOT COMPLETED | Pazopanib Arm | 22 |
Source ClinicalTrials.gov
Adverse events158
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Vomiting G1 | Gastrointestinal disorders | Pazopanib Arm | 6 | 25 | 6 |
| other | Intermittent vomiting G1 | Gastrointestinal disorders | Pazopanib Arm | 4 | 25 | 4 |
| other | Vomiting G2 | Gastrointestinal disorders | Pazopanib Arm | 1 | 25 | 1 |
| other | Vomiting G3 | Gastrointestinal disorders | Pazopanib Arm | 1 | 25 | 1 |
| other | Fatigue G1 | General disorders | Pazopanib Arm | 5 | 25 | 7 |
| other | Fatigue G2 | General disorders | Pazopanib Arm | 8 | 25 | 8 |
| other | Intermittent nausea G1 | Gastrointestinal disorders | Pazopanib Arm | 3 | 25 | 3 |
| other | Nausea G1 | Gastrointestinal disorders | Pazopanib Arm | 6 | 25 | 7 |
| other | Nausea G2 | Gastrointestinal disorders | Pazopanib Arm | 1 | 25 | 1 |
| other | Nausea G3 | Gastrointestinal disorders | Pazopanib Arm | 1 | 25 | 1 |
1 to 10 of 158Source ClinicalTrials.gov
See all 158 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib Arm | ||
| Total, other adverse events | Pazopanib Arm | 25 | 25 |
| Total, serious adverse events | Pazopanib Arm | 14 | 25 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01391611
GET https://conductscience.org/api/trials/v1/NCT01391611/events?page=2